98%
921
2 minutes
20
Aims: Bariatric surgery (BS) reduces obesity-associated systemic inflammation leading to multiple cardiovascular (CV) and metabolic benefits. Here, we tested whether measuring vaso-inflammatory cytokines, gut hormones, and circulating extracellular vesicles (EV) provide vaso-inflammatory-metabolic signatures that better correlate to CV-metabolic outcomes after BS, compared to a standard clinical assessment including body weight (BW) loss and traditional CV risk factors.
Methods: In 111 patients with severe obesity, conventional clinical-biochemical parameters and non-conventional vaso-inflammatory-metabolic markers were analyzed at baseline, after 1- (T12) and 3-years (T36) post-BS and were associated to post-surgical BW loss and improvement of patients' CV-metabolic profile.
Results: BW decreased from a median of 111 to 77 Kg at T36 (30 Kg and 32.8% BMI cumulative reduction), and all traditional CV risk factors improved after BS. However, the baseline evaluation of these parameters was unable to discriminate patients according to their CV-metabolic outcome, after BS. This objective was achieved combining the decrease in circulating serum amyloid associated protein, IL-6, TNF-α, and insulin after BS, together with the increase of GLP-1, ghrelin, PYY and bile acids, and changes in EV profiling. Of note, a specific signature given by the reduced expression of several surface antigens carried by EVs and specific single EV markers (i.e., derived from endothelium, platelets, inflammatory cells), successfully discriminated patients at baseline according to their CV-metabolic post-surgical outcome.
Conclusions: Non-conventionally measured vaso-inflammatory-metabolic signatures, and in particular EV profiling, are associated with CV-metabolic outcome after BS and may be integrated to conventional parameters to improve the management and risk stratification of these patients.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1093/eurjpc/zwaf561 | DOI Listing |
Diabetes Res Clin Pract
September 2025
Department of Intensive Care Medicine, Chi Mei Medical Center, Tainan, Taiwan; School of Medicine, College of Medicine, National Sun Yat-sen University, Kaohsiung, Taiwan. Electronic address:
Obes Surg
September 2025
Department of Nephrology, Xinqiao Hospital, Army Medical University, Chongqing, China.
Obes Surg
September 2025
Department of Medical and Surgical Sciences, Internal Medicine Unit, Columbus-Gemelli Hospital, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy.
Obesity is a globally prevalent condition associated with elevated morbidity and mortality. Metabolic and bariatric surgery offers a definitive treatment for class III (BMI > 40) obesity, achieving substantial, enduring weight loss and improving metabolic health. Despite extensive research on the physical benefits, comparatively fewer reviews investigate the psychosocial and relational changes accompanying these procedures.
View Article and Find Full Text PDFObes Surg
September 2025
Department of Minimally Invasive Digestive Surgery, Antoine Béclère Hospital, AP-HP, 157 Rue de La Porte de Trivaux, 92141 Clamart, Clamart, France.
Background: Bariatric surgery (BS) is the most effective treatment for severe obesity, but a significant proportion of patients experience insufficient weight loss (IWL) or weight regain. Glucagon-like peptide-1 receptor agonists (arGLP-1) have emerged as a promising adjunctive therapy for managing these suboptimal outcomes. This study evaluates the efficacy and safety of arGLP-1 in patients with IWL or WR after BS.
View Article and Find Full Text PDFJ Arthroplasty
September 2025
Virginia Commonwealth University Health System, Department of Orthopaedic Surgery, 1200 E Broad St, Richmond, VA, 23298, USA.
Introduction: Obesity is an increasingly prevalent comorbidity that confers greater risks of postoperative complications following total joint arthroplasty, underscoring the need for viable preoperative weight loss. The objective of this study was to compare the risk of 90-day adverse events in patients undergoing total knee arthroplasty (TKA) following bariatric surgery versus treatment with glucagon-like peptide-1 receptor agonists (GLP-1 RA).
Methods: A retrospective review of a national research network from May 1, 2005, to February 12, 2025, identified patients undergoing TKA with bariatric surgery or GLP-1 RA prescriptions in the 18 months preceding their joint arthroplasty.